Organovo raised millions of dollars from investors to fuel its goal of developing 3D “bioprinted” human tissues for use in people with end-stage liver disease and other life-threatening illnesses.
But the San Diego company fell short of bringing its lead regenerative medicine program into clinical trials, and now it is charting a course as a vehicle for privately held cancer drug developer Tarveda Therapeutics to join the public markets.
Under the deal, announced Monday, Tarveda shareholders will own 75 percent of the combined company; Organovo shareholders, 25 percent. The boards of directors of the companies have approved the transaction,… Read more »
UNDERWRITERS AND PARTNERS